454 related articles for article (PubMed ID: 28380420)
21. Establishment of radioactive astatine and iodine uptake in cancer cell lines expressing the human sodium/iodide symporter.
Petrich T; Helmeke HJ; Meyer GJ; Knapp WH; Pötter E
Eur J Nucl Med Mol Imaging; 2002 Jul; 29(7):842-54. PubMed ID: 12111124
[TBL] [Abstract][Full Text] [Related]
22. Radiation-Induced Amplification of TGFB1-Induced Mesenchymal Stem Cell-Mediated Sodium Iodide Symporter (
Schug C; Kitzberger C; Sievert W; Spellerberg R; Tutter M; Schmohl KA; Eberlein B; Biedermann T; Steiger K; Zach C; Schwaiger M; Multhoff G; Wagner E; Nelson PJ; Spitzweg C
Clin Cancer Res; 2019 Oct; 25(19):5997-6008. PubMed ID: 31196853
[TBL] [Abstract][Full Text] [Related]
23. In vivo molecular imaging and radionuclide (131I) therapy of human nasopharyngeal carcinoma cells transfected with a lentivirus expressing sodium iodide symporter.
Shi S; Zhang M; Guo R; Miao Y; Hu J; Xi Y; Li B
PLoS One; 2015; 10(1):e0116531. PubMed ID: 25621996
[TBL] [Abstract][Full Text] [Related]
24. Treatment of prostate cancer by radioiodine therapy after tissue-specific expression of the sodium iodide symporter.
Spitzweg C; O'Connor MK; Bergert ER; Tindall DJ; Young CY; Morris JC
Cancer Res; 2000 Nov; 60(22):6526-30. PubMed ID: 11103823
[TBL] [Abstract][Full Text] [Related]
25. A transporter gene (sodium iodide symporter) for dual purposes in gene therapy: imaging and therapy.
Cho JY
Curr Gene Ther; 2002 Dec; 2(4):393-402. PubMed ID: 12477251
[TBL] [Abstract][Full Text] [Related]
26. Effective control of tumor growth through spatial and temporal control of theranostic sodium iodide symporter (
Tutter M; Schug C; Schmohl KA; Urnauer S; Schwenk N; Petrini M; Lokerse WJM; Zach C; Ziegler S; Bartenstein P; Weber WA; Wagner E; Lindner LH; Nelson PJ; Spitzweg C
Theranostics; 2020; 10(10):4490-4506. PubMed ID: 32292510
[No Abstract] [Full Text] [Related]
27. Image-guided radioiodide therapy of medullary thyroid cancer after carcinoembryonic antigen promoter-targeted sodium iodide symporter gene expression.
Spitzweg C; Baker CH; Bergert ER; O'Connor MK; Morris JC
Hum Gene Ther; 2007 Oct; 18(10):916-24. PubMed ID: 17931047
[TBL] [Abstract][Full Text] [Related]
28. Image-guided, tumor stroma-targeted 131I therapy of hepatocellular cancer after systemic mesenchymal stem cell-mediated NIS gene delivery.
Knoop K; Kolokythas M; Klutz K; Willhauck MJ; Wunderlich N; Draganovici D; Zach C; Gildehaus FJ; Böning G; Göke B; Wagner E; Nelson PJ; Spitzweg C
Mol Ther; 2011 Sep; 19(9):1704-13. PubMed ID: 21587211
[TBL] [Abstract][Full Text] [Related]
29. In vivo radioiodide imaging and treatment of breast cancer xenografts after MUC1-driven expression of the sodium iodide symporter.
Dwyer RM; Bergert ER; O'connor MK; Gendler SJ; Morris JC
Clin Cancer Res; 2005 Feb; 11(4):1483-9. PubMed ID: 15746050
[TBL] [Abstract][Full Text] [Related]
30. In vivo radioiodide imaging and treatment of pancreatic cancer xenografts after MUC1 promoter-driven expression of the human sodium-iodide symporter.
Chen RF; Li ZH; Pan QH; Zhou JJ; Tang QB; Yu FY; Zhou QB; Wang J; Chen JS
Pancreatology; 2007; 7(5-6):505-13. PubMed ID: 17912014
[TBL] [Abstract][Full Text] [Related]
31. The sodium iodide symporter (NIS): novel applications for radionuclide imaging and treatment.
Spitzweg C; Nelson PJ; Wagner E; Bartenstein P; Weber WA; Schwaiger M; Morris JC
Endocr Relat Cancer; 2021 Sep; 28(10):T193-T213. PubMed ID: 34259647
[TBL] [Abstract][Full Text] [Related]
32. Development of a sodium/iodide symporter (NIS)-transgenic mouse for imaging of cardiomyocyte-specific reporter gene expression.
Kang JH; Lee DS; Paeng JC; Lee JS; Kim YH; Lee YJ; Hwang DW; Jeong JM; Lim SM; Chung JK; Lee MC
J Nucl Med; 2005 Mar; 46(3):479-83. PubMed ID: 15750162
[TBL] [Abstract][Full Text] [Related]
33. Genetically targeted radiotherapy of head and neck squamous cell carcinoma using the sodium-iodide symporter (NIS).
Gaut AW; Niu G; Krager KJ; Graham MM; Trask DK; Domann FE
Head Neck; 2004 Mar; 26(3):265-71. PubMed ID: 14999802
[TBL] [Abstract][Full Text] [Related]
34. Experimental targeted radioiodide therapy following transfection of the sodium iodide symporter gene: effect on clonogenicity in both two-and three-dimensional models.
Carlin S; Cunningham SH; Boyd M; McCluskey AG; Mairs RJ
Cancer Gene Ther; 2000 Dec; 7(12):1529-36. PubMed ID: 11228531
[TBL] [Abstract][Full Text] [Related]
35. Dual EGFR- and TfR-targeted gene transfer for sodium iodide symporter gene therapy of glioblastoma.
Spellerberg R; Benli-Hoppe T; Kitzberger C; Hageneier M; Schwenk N; Öztürk Ö; Steiger K; Multhoff G; Eiber M; Schilling F; Weber WA; Kälin RE; Glass R; Nelson PJ; Wagner E; Spitzweg C
Mol Ther Oncolytics; 2022 Dec; 27():272-287. PubMed ID: 36458201
[TBL] [Abstract][Full Text] [Related]
36. Enhancement of human sodium iodide symporter gene therapy for breast cancer by HDAC inhibitor mediated transcriptional modulation.
Kelkar MG; Senthilkumar K; Jadhav S; Gupta S; Ahn BC; De A
Sci Rep; 2016 Jan; 6():19341. PubMed ID: 26777440
[TBL] [Abstract][Full Text] [Related]
37. Efficacy of 99mTc pertechnetate and 131I radioisotope therapy in sodium/iodide symporter (NIS)-expressing neuroendocrine tumors in vivo.
Schipper ML; Riese CGU; Seitz S; Weber A; Béhé M; Schurrat T; Schramm N; Keil B; Alfke H; Behr TM
Eur J Nucl Med Mol Imaging; 2007 May; 34(5):638-650. PubMed ID: 17160413
[TBL] [Abstract][Full Text] [Related]
38. Telomerase-driven expression of the sodium iodide symporter (NIS) for in vivo radioiodide treatment of cancer: a new broad-spectrum NIS-mediated antitumor approach.
Riesco-Eizaguirre G; De la Vieja A; Rodríguez I; Miranda S; Martín-Duque P; Vassaux G; Santisteban P
J Clin Endocrinol Metab; 2011 Sep; 96(9):E1435-43. PubMed ID: 21697253
[TBL] [Abstract][Full Text] [Related]
39. Sodium iodide symporter-mediated radioiodide imaging and therapy of ovarian tumor xenografts in mice.
Dwyer RM; Bergert ER; O'Connor MK; Gendler SJ; Morris JC
Gene Ther; 2006 Jan; 13(1):60-6. PubMed ID: 16121204
[TBL] [Abstract][Full Text] [Related]
40. Radioiodide treatment after sodium iodide symporter gene transfer is a highly effective therapy in neuroendocrine tumor cells.
Schipper ML; Weber A; Béhé M; Göke R; Joba W; Schmidt H; Bert T; Simon B; Arnold R; Heufelder AE; Behr TM
Cancer Res; 2003 Mar; 63(6):1333-8. PubMed ID: 12649195
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
